Mitotech Russia received approval for marketing Visomitin in Russia

Mitotech LLC , a Moscow State University based company, has completed a Phase I/II study of its first drug Visomitin. The multi-center study demonstrated drug’s safety and efficacy against dry eye syndrome. Mitotech LLC will seek market approval for Visomitin from the Russian Ministry of Health in 2011-2012 timeframe.